Authors
Anushka Patel, Alan Cass, David Peiris, Tim Usherwood, Alex Brown, Stephen Jan, Bruce Neal, Graham S Hillis, Natasha Rafter, Andrew Tonkin, Ruth Webster, Laurent Billot, Severine Bompoint, Carol Burch, Hugh Burke, Noel Hayman, Barbara Molanus, Christopher M Reid, Louise Shiel, Samantha Togni, Anthony Rodgers, Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration
Publication date
2015/7
Journal
European journal of preventive cardiology
Volume
22
Issue
7
Pages
920-930
Publisher
SAGE Publications
Description
Background
Most individuals at high cardiovascular disease (CVD) risk worldwide do not receive any or optimal preventive drugs. We aimed to determine whether fixed dose combinations of generic drugs (‘polypills’) would promote use of such medications.
Methods
We conducted a randomized, open-label trial involving 623 participants from Australian general practices. Participants had established CVD or an estimated five-year CVD risk of ≥15%, with indications for antiplatelet, statin and ≥2 blood pressure lowering drugs (‘combination treatment’). Participants randomized to the ‘polypill-based strategy’ received a polypill containing aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12.5 mg. Participants randomized to ‘usual care’ continued with separate medications and doses as prescribed by their doctor. Primary outcomes were self-reported combination …
Scholar articles
A Patel, A Cass, D Peiris, T Usherwood, A Brown… - European journal of preventive cardiology, 2015